Literature DB >> 1548759

Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

J Kimpton1, M Emerman.   

Abstract

We have constructed a HeLa cell line that both expresses high levels of CD4 and contains a single integrated copy of a beta-galactosidase gene that is under the control of a truncated human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). This cell line, called CD4-LTR/beta-gal, can be used to determine quantitatively the titer of laboratory-adapted HIV strains, and the method used to do so is as sensitive as the determination of viral titers in a T-cell line by end point dilution. Using this cell line as a titer system, we calculated that HIV-1 stocks contain only one infectious particle per 3,500 to 12,000 virions. Virus derived from a molecular clone of a macrophagetropic provirus will not infect this cell line. We have also cocultivated peripheral blood lymphocyte cultures from HIV-infected individuals with the CD4-LTR/beta-gal indicator cells. In a majority of primary isolates (five of eight), including isolates from asymptomatic patients, rare virus-infected cells that can activate the beta-galactosidase gene are present.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548759      PMCID: PMC289016     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Transcellular transactivation by the human immunodeficiency virus type 1 tat protein.

Authors:  D E Helland; J L Welles; A Caputo; W A Haseltine
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.

Authors:  W A O'Brien; Y Koyanagi; A Namazie; J Q Zhao; A Diagne; K Idler; J A Zack; I S Chen
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

3.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

4.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

5.  High specific infectivity avian RNA tumor viruses.

Authors:  R E Smith
Journal:  Virology       Date:  1974-08       Impact factor: 3.616

6.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

7.  Receptor interference groups of 20 retroviruses plating on human cells.

Authors:  M A Sommerfelt; R A Weiss
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

8.  HIV-1 indicator cell lines.

Authors:  A Akrigg; G W Wilkinson; S Angliss; P J Greenaway
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

9.  New retrovirus helper cells with almost no nucleotide sequence homology to retrovirus vectors.

Authors:  J P Dougherty; R Wisniewski; S L Yang; B W Rhode; H M Temin
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

10.  Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane.

Authors:  S S Rhee; H X Hui; E Hunter
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

View more
  474 in total

1.  Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

Authors:  I Muñoz-Barroso; K Salzwedel; E Hunter; R Blumenthal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

3.  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

Authors:  E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Modulation of HIV-1 replication by a novel RhoA effector activity.

Authors:  L Wang; H Zhang; P A Solski; M J Hart; C J Der; L Su
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

7.  Deletion mutagenesis downstream of the 5' long terminal repeat of human immunodeficiency virus type 1 is compensated for by point mutations in both the U5 region and gag gene.

Authors:  C Liang; L Rong; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Duplication of the primary encapsidation and dimer linkage region of human immunodeficiency virus type 1 RNA results in the appearance of monomeric RNA in virions.

Authors:  J Sakuragi ; T Shioda; A T Panganiban
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.